R&D | October 28, 2025
MilliporeSigma partners with Promega to advance 3-D cell drug discovery technologies
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis
The event will be attended by 35,000+ industry professionals
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
_256_384.jpg)
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
The company’s “greener” initiatives emphasize eco-friendly excipients and energy-efficient manufacturing processes that reduce environmental impact without compromising product quality
Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients
The submissions are supported by data from the Phase 3 KEYNOTE-905 trial
The initial $100 million will fund a state-of-the-art hard-shell capsule facility in Atlanta
Subscribe To Our Newsletter & Stay Updated
